These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

754 related items for PubMed ID: 23494648

  • 21. Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity.
    Regev K, Healy BC, Khalid F, Paul A, Chu R, Tauhid S, Tummala S, Diaz-Cruz C, Raheja R, Mazzola MA, von Glehn F, Kivisakk P, Dupuy SL, Kim G, Chitnis T, Weiner HL, Gandhi R, Bakshi R.
    JAMA Neurol; 2017 Mar 01; 74(3):275-285. PubMed ID: 28114622
    [Abstract] [Full Text] [Related]

  • 22. A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.
    Ziemssen T, Piani-Meier D, Bennett B, Johnson C, Tinsley K, Trigg A, Hach T, Dahlke F, Tomic D, Tolley C, Freedman MS.
    J Med Internet Res; 2020 Feb 12; 22(2):e16932. PubMed ID: 32049062
    [Abstract] [Full Text] [Related]

  • 23. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E, Lee JC, Nakamura K, Rudick RA.
    Ann Neurol; 2008 Sep 12; 64(3):255-65. PubMed ID: 18661561
    [Abstract] [Full Text] [Related]

  • 24. Cortical dysfunction underlies disability in multiple sclerosis.
    Vucic S, Burke T, Lenton K, Ramanathan S, Gomes L, Yannikas C, Kiernan MC.
    Mult Scler; 2012 Apr 12; 18(4):425-32. PubMed ID: 21965421
    [Abstract] [Full Text] [Related]

  • 25. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S, Ormeci B, Idiman E.
    J Neurol Sci; 2005 May 15; 232(1-2):65-9. PubMed ID: 15850584
    [Abstract] [Full Text] [Related]

  • 26. Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis.
    Regev K, Paul A, Healy B, von Glenn F, Diaz-Cruz C, Gholipour T, Mazzola MA, Raheja R, Nejad P, Glanz BI, Kivisakk P, Chitnis T, Weiner HL, Gandhi R.
    Neurol Neuroimmunol Neuroinflamm; 2016 Oct 15; 3(5):e267. PubMed ID: 27606352
    [Abstract] [Full Text] [Related]

  • 27. Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression.
    Ibrahim SH, El-Mehdawy KM, Seleem M, El-Sawalhi MM, Shaheen AA.
    J Neuroimmunol; 2020 Oct 15; 347():577356. PubMed ID: 32781341
    [Abstract] [Full Text] [Related]

  • 28. Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study.
    Haghikia A, Haghikia A, Hellwig K, Baraniskin A, Holzmann A, Décard BF, Thum T, Gold R.
    Neurology; 2012 Nov 27; 79(22):2166-70. PubMed ID: 23077021
    [Abstract] [Full Text] [Related]

  • 29. Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus.
    Wang H, Peng W, Ouyang X, Li W, Dai Y.
    Transl Res; 2012 Sep 27; 160(3):198-206. PubMed ID: 22683424
    [Abstract] [Full Text] [Related]

  • 30. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
    Muris AH, Rolf L, Broen K, Hupperts R, Damoiseaux J, Smolders J.
    J Steroid Biochem Mol Biol; 2016 Nov 27; 164():254-257. PubMed ID: 26598277
    [Abstract] [Full Text] [Related]

  • 31. The identification of up-regulated ebv-miR-BHRF1-2-5p targeting MALT1 and ebv-miR-BHRF1-3 in the circulation of patients with multiple sclerosis.
    Wang YF, He DD, Liang HW, Yang D, Yue H, Zhang XM, Wang R, Li B, Yang HX, Liu Y, Chen Y, Duan YX, Zhang CY, Chen X, Fu J.
    Clin Exp Immunol; 2017 Jul 27; 189(1):120-126. PubMed ID: 28253538
    [Abstract] [Full Text] [Related]

  • 32. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE, Sombekke M, van Winsen L, Killestein J, Barkhof F, Polman CH, Dijkstra CD, Blankenstein MA, Pratico D.
    Mult Scler; 2012 Aug 27; 18(8):1092-8. PubMed ID: 22695538
    [Abstract] [Full Text] [Related]

  • 33. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
    Calabrese M, Rocca MA, Atzori M, Mattisi I, Favaretto A, Perini P, Gallo P, Filippi M.
    Ann Neurol; 2010 Mar 27; 67(3):376-83. PubMed ID: 20373349
    [Abstract] [Full Text] [Related]

  • 34. Differential intracellular expression of CCR5 and chemokines in multiple sclerosis subtypes.
    Jalonen TO, Pulkkinen K, Ukkonen M, Saarela M, Elovaara I.
    J Neurol; 2002 May 27; 249(5):576-83. PubMed ID: 12021948
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of patients with multiple sclerosis using a combination of morphometrical features and clinical scores.
    Varoğlu AO, Odaci E, Gumus H, Keles ON, Unal B, Deniz O.
    J Clin Neurosci; 2010 Feb 27; 17(2):191-5. PubMed ID: 20036126
    [Abstract] [Full Text] [Related]

  • 36. Plasma S100beta and NSE levels and progression in multiple sclerosis.
    Koch M, Mostert J, Heersema D, Teelken A, De Keyser J.
    J Neurol Sci; 2007 Jan 31; 252(2):154-8. PubMed ID: 17187827
    [Abstract] [Full Text] [Related]

  • 37. Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.
    Vistbakka J, Sumelahti ML, Lehtimäki T, Elovaara I, Hagman S.
    Acta Neurol Scand; 2018 Aug 31; 138(2):130-136. PubMed ID: 29527713
    [Abstract] [Full Text] [Related]

  • 38. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS.
    Sellebjerg F, Börnsen L, Khademi M, Krakauer M, Olsson T, Frederiksen JL, Sørensen PS.
    Neurology; 2009 Dec 08; 73(23):2003-10. PubMed ID: 19996075
    [Abstract] [Full Text] [Related]

  • 39. Association between circulating MicroRNAs (hsa-miR-92a-1* and hsa-miR-454) and multiple sclerosis phenotypes and activity status.
    Moharram AA, Amer HA, Bakr SI, Fouad NT, Zamzam D, M R.
    Egypt J Immunol; 2022 Apr 08; 29(2):10-18. PubMed ID: 35436050
    [Abstract] [Full Text] [Related]

  • 40. Identification of MS-specific serum miRNAs in an international multicenter study.
    Regev K, Healy BC, Paul A, Diaz-Cruz C, Mazzola MA, Raheja R, Glanz BI, Kivisäkk P, Chitnis T, Jagodic M, Piehl F, Olsson T, Khademi M, Hauser S, Oksenberg J, Khoury SJ, Weiner HL, Gandhi R.
    Neurol Neuroimmunol Neuroinflamm; 2018 Sep 08; 5(5):e491. PubMed ID: 30175165
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.